Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share from the same period last year.